tbuckley/cabot-search huggingface dataset:
AB0065 Galectin-3 Is A Major Determinant of Femoral Neck Bone Mineral Density in A Partial Regression Model: A Preliminary Study
Authors: C. Ko, Y.-J. Su
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Low bone mass is an essential extra-articular feature of rheumatoid arthritis (RA). Patients with RA might present an increased risk of low bone mass as a result of systemic inflammation by alteration of the RANK/RANKL/osteoprotegerin and Wnt/ catenin pathways. In RA, serum galectin-3 correlated with C-reactive protein levels and was considered as biomarker of inflammation. However, recent studies showed abundant galectin-3 observed in the area of severe bone destruction may act as a negative regulator for the upregulated osteoclastogenesis. The role of Galectin-3 is unclear in the regulation of bone resorption in RA. <h3>Objectives</h3> The objectives of our study were to evaluate bone mineral density (BMD) and the levels of Galactin-3 and Dkk-1 in RA patients and to study the relation between these parameters. <h3>Methods</h3> Patients with active RA were checked with galactin-3, Dkk-1 and followed up with BMD assessment and inflammatory evaluation by ultrasonography (US). Serum galectin-3, Dkk-1 concentrations were assayed with ELISA assay. BMD was measured at hip neck by a Dual-energy X-ray absorptiometry (DXA) (Explorer; Hologic Inc., USA). Grey scale and Power doppler US were graded using a 4-grade semiquantitative scoring system, on a scale of 0–3 at wrist. Each wrist was scanned from lateral to medial aspects in longitudinal planes Radius-Lunate-capitate (volar and dorsal), dorsal Radius-scaphoid-trapezoid, and dorsal Ulna-triquetral. Demographic and clinical data, DAS-28, and erythrocyte sedimentation rate (ESR) were recorded for each patient. Correlations between variables and multilinear regression analysis were performed to check serum galectin-3 expression levels and BMD parameters. <h3>Results</h3> (1) Six RA patients 50% were female, age was 57.3±4.4 years, disease duration was 6.9±3.8 years and disease activity DAS 28 was 6.33±0.31. (2) The galectin-3, Sonography inflammatory score and serum iPTH levels showed a significant negative association with BMD at the hip.(Table.1) (3) The multilinear regression analysis showed iPTH, Galactin3 and US score were found to explain 99% of the variance in BMD in hip neck.(4) However, the galectin-3 in multilinear regression analysis showed a positive association with BMD at the hip. (correlation coefficient=0.126, <i>p</i> value=0.014) (Table.2) <h3>Conclusions</h3> Galectin-3 is a major determinant of femoral neck BMD in this partial regression model, after controlling iPTH and sonography inflammatory score, in our preliminary study. <h3>References</h3> Diarra, Danielle, et al. Nature medicine 13.2 (2007): 156–163. Ohshima, Shiro, et al. Arthritis &amp; Rheumatism 48.10 (2003): 2788–2795. Li, Yin-Ji, et al. Laboratory Investigation 89.1 (2009): 26–37. <h3>Disclosure of Interest</h3> None declared
OP0162 Toll-like Receptor 7-, but Not Toll-like Receptor 9-, Mediated Interferon-α Production from Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus
Authors: K. Sakata, S. Nakayamada, Y. Miyazaki, S. Kubo, K. Nakano, Y. Tanaka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Characteristic induction of interferon (IFN) signature is known to play a pivotal role in patients with SLE and plasmacytoid dendritic cells (pDC) are major source of Type I IFN. However, mechanisms of Type I IFN production from pDC in the pathogenesis of SLE remain unclear. <h3>Objectives</h3> To elucidate the function of pDC in SLE, we shed light upon Toll-like receptor (TLR) 7 and TLR9-mediated signaling during Type I IFN production from pDC in patients with SLE or healthy controls (HC). <h3>Methods</h3> Peripheral blood mononuclear cells (PBMCs) in 68 SLE patients without hydroxychloroquin treatment, 37 RA patients and 24 HC were analyzed in the presence of a TLR7 agonist loxoribine and a TLR9 agonist CpG 2216. The IFN-α production in Lin-HLA-DR+CD123+CD11c- pDCs was detected by flow cytometry. <h3>Results</h3> The spontaneous production of IFN-α in pDCs was marginal, but the TLR7 agonist markedly up-regulated IFN-α production from pDCs in SLE patients compared to that in HC. Such an up-regulation of IFN-α was not observed in pDCs in RA. On the other hands, TLR9-mediated IFN-α production from pDCs in SLE was down-regulated compared to that in HC. Furthermore, TLR7- and TLR9-mediated IFN-α production from pDCs in SLE patients were positively and negatively correlated with SLEDAI and dsDNA-ab titers, respectively. The expression of TLR7 and TLR9 on pDCs was comparable among SLE, RA and HC, indicating that the difference of TLR response was not depend on alterations of TLR expression levels. By in vitro experiments under pre-treatment with multiple cytokines, both Type I and Type II IFN up-regulated the TLR7-mediated IFN-α production from pDCs, but they down-regulated the TLR9-mediated IFN-α production, suggesting that up-regulation of TLR7 responses and down-regulation of TLR9 responses of pDCs in SLE patients were regulated by Type I and Type II IFNs. <h3>Conclusions</h3> This is the first report demonstrated the differential regulation of TLR7 and TLR9 by type I IFN in pDCs in SLE patients, namely, TLR7 and TLR9 response were regulated by Type I and Type II IFNs. Taken together, TLR7-mediated pDC response plays a pivotal role in the increase in IFN-signature in SLE patients and could be a potential therapeutic target for SLE. <h3>Disclosure of Interest</h3> K. Sakata Employee of: Mitsubishi Tanabe Pharma Corporation, S. Nakayamada: None declared, Y. Miyazaki: None declared, S. Kubo: None declared, K. Nakano: None declared, Y. Tanaka Grant/research support from: Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, Abbvie, Bristol-Myers., Consultant for: Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD, Santen
Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study
Authors: Eldad J Dann, Osnat Bairey, Rachel Bar-Shalom, Elinor Sabbag, Marina Izak, Abraham Korenberg, Luiza Akria, Dina Attias, Kalman Filanovsky, Uri Abadi, Rosa Ruchlemer, Roxolyana Abdah-Bortnyak, Neta Goldschmidt, Ron Epelbaum, Netanel Horowitz, David Lavie, Dina Ben Yehuda, Ofer Shpilberg, Ora B. Paltiel
Journal: Blood (2014)
The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Severe Aplastic Anemia.
Authors: Jong Wook Lee, Byung Sik Cho, Yoo-Jin Kim, Hee Je Kim, Seok Lee, Chang Ki Min, Seok Goo Cho, Woo Sung Min, Chong Won Park, Chun Choo Kim
Journal: Blood (2009)
Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
Authors: Tadao Ishida, Hideo Kimura, Koumei Kubo, Kazutaka Sunami, Shuji Ozaki, Naoki Takezako, Hiroshi Handa, Hiroshi Kosugi, Hirokazu Murakami, Kazuyuki Shimizu
Journal: Blood (2015)
What next for refugees after demolition of the Calais camp?
Authors: Frédérique Drogoul, Samuel Hanryon
Journal: BMJ (2016)

For most of 2016, whenever one of us visited the Medecins Sans Frontieres (MSF) project in the refugee settlement in Calais, France, we would find new fences, new walls, and new areas where trees were cut down to enable police surveillance of residents. Surrounded by barriers on all sides, “the jungle”—the name for this migrant camp located near a main port for crossing the English Channel into the UK—was built on a former industrial waste site. It is no place to live.

Last month’s dismantlement of the 6000 plus person camp began relatively calmly. Thousands of residents had fled before authorities began the process of moving them to temporary “reception centres” around France. When the eviction started, the general mood ranged from relief, particularly among those who hoped to settle in France, to resignation or anger among others who hoped to join relatives or friends in the UK.

But the situation quickly degenerated. Much of the camp was burnt to the ground, and many people had to avoid the fires to find somewhere to sleep. Official plans …
Delineation of Promoter Methylation in Patients with Myelodysplastic Syndromes: Widespread and Concurrent Hypermethylation of Multiple Genes and Increased mRNA Expression of the DNA Methyltransferases DNMT1, 3A and 3B.
Authors: Anni Aggerholm, Mette S. Holm, Per Guldberg, Peter Hokland
Journal: Blood (2004)
Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.
Authors: Giovanni Carulli, Sara Galimberti, Giuseppina Bianchi, Alessandra Zucca, Enrico Orciuolo, Gabriele Buda, Giulia Cervetti, Mario Petrini
Journal: Blood (2005)
Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering
Authors: Fatima Rodriguez, Robert A. Harrington
Journal: JAMA (2016)

This Viewpoint discusses the role of implementation and translational science and digital platforms for improving population cardiovascular risk and advancing precision treatments in an era of intensive statin therapy and PCSK9 inhibitors.
Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy
Authors: Ahmad Zarzour, Aziz Nazha, Matt Kalaycio, Bhumika J. Patel, Aaron T. Gerds, Michael J. Clemente, Cassandra M Hirsch, Jennifer S. Carew, Anjali S. Advani, Srinivasa R. Sanikommu, Bartlomiej Przychodzen, Hetty E. Carraway, Sudipto Mukherjee, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2015)
Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey
Authors: Christine R. Totri, Lawrence F. Eichenfield, Kirsty Logan, Laura Proudfoot, Jochen Schmitt, Irene Lara-Corrales, Jeffrey Sugarman, Wynnis Tom, Elaine Siegfried, Kelly Cordoro, Amy S. Paller, Carsten Flohr
Journal: Journal of the American Academy of Dermatology (2016)
Efficient Hematopoietic Differentiation of Common Marmoset Embryonic Stem Cells by the Inhibition of Their Self-Renewal Pathway.
Authors: Takenobu Nii, Tomotoshi Marumoto, Hirotaka Kawano, Saori Yamaguchi, Yoko Nagai, Jiyuan Liao, Michiyo Okada, Yoshie Miura, Kenzaburo Tani
Journal: Blood (2012)
Margaret McCartney: What Hunt did next
Authors: Margaret McCartney
Journal: BMJ (2016)

Jeremy Hunt has pinned his NHS badge back on. “Let’s not argue about statistics,” he said recently.1

In his Conservative Party conference speech, however, the health secretary was talking about four key standards that the Academy of Medical Royal Colleges recommends. One was that, “whatever day of the week it is, highly vulnerable patients should be checked by a consultant twice a day.” Hunt said that this happens “in just one in 20 hospitals.” He added that “patients should be checked by a senior doctor within 14 hours of being admitted,” which was happening “in just one in 10 hospitals.”2

Let us, indeed, …
A Prognostic Model Using ZAP- 70, CD38 and Cytogenetics To Better Predict Need for Early Therapy and Response to Treatment in Chronic Lymphocytic Leukemia (CLL).
Authors: Peter Acs, Blanche Mavromatis, Metin Ozdemirly, Daniel Hartmann, Jean Meck, Emre Zafer, Rebecca Slack, Bruce Cheson
Journal: Blood (2005)
THU0316 Ischemic Heart Disease among SLE Patients: A Case-Control Study:
Authors: A. Abu Much, A. Watad, D. Bracco, A.D. Cohen, H. Amital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ischemic heart disease (IHD) is a well identified cause of mortality in SLE patients due to accelerated premature atherosclerosis attributed to both traditional cardiovascular risk factors and to the inflammatory effect of SLE itself (1,2). <h3>Objectives</h3> To investigate the incidence and prevalence of IHD among Middle Eastern SLE patients derived from a large, national real-life database. <h3>Methods</h3> Using data from the largest HMO in Israel, the Clalit Health Services, we selected for patients with SLE. These patients were compared with age and sex matched controls with regards to the prevalence of IHD in a case-control study. Chi-square and t-tests were used for univariate analysis and a logistic regression model was used for multivariate analysis. <h3>Results</h3> The study included 5,018 patients with SLE and 25,090 age and sex-frequency matched controls. The prevalence of IHD in patients with SLE was increased compared to controls (11.3% and 3.1%, respectively, P&lt;0.001). In a multivariate analysis SLE was associated with IHD (OR 3.77, 95% confidence interval 3.34–4.26). <h3>Conclusions</h3> Our data supports that SLE is an independent risk factor for IHD. When evaluating by gender, the risk seems even more substantial in females. <h3>References</h3> Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS).Ann Rheum Dis. 2011;70:760–5 Romero-Díaz J, Vargas-Vόracková F, Kimura-Hayama E, Cortázar-Benítez LF,Gijόn-Mitre R, Criales S, Cabiedes-Contreras J, Iñiguez-Rodríguez Mdel R,Lara-García EA, Núñez-Alvarez C, Llorente L, Aguilar-Salinas C, Sánchez-Guerrero J. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford). 2012;51:110–9. <h3>Disclosure of Interest</h3> None declared
SAT0272 Survival of Biological Treatment in Patients with Juvenile Idiopathic Arthritis Non-Systemic
Authors: H. Moruno-Cruz, A. Pérez Gόmez, D. Clemente Garulo, J.C. Lόpez Robledillo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Currently we have biological treatments for control juvenile idiopathic arthritis (JIA), we have specific protocols that help us to handle, and do not know the exact time they keep these treatment, which conducted this study survival the biological agent. <h3>Objectives</h3> The purpose this work is describe the survival time of biological drugs used in patients diagnosed with JIA, excluding the form systemic, in a pediatric unit of a children9s hospital in the last 5 years. <h3>Methods</h3> Descriptive analytic study of patients diagnosed with JIA (non-systemic) (as proposed by ILAR nomenclature, Edmonton 2001), who received biological treatment from 1 January 2010 to 30 June 2015. It considered as an event end the suspension of treatment by state remission or change to regimen decrease. Statistical analysis performed using the Kaplan-Meier and log rank test with SPSS.19.0 program. <h3>Results</h3> Total 90 patients diagnosed with JIA with biological treatment in the last 5 years, 2/3 female (60 girls, 66.7%), 1/3 male (30 boys, 33.3%), mean age 5 years 2 months (minimum: 1 year 11 months, maximum: 15 years 6 months). The distribution of JIA: Oligoarticular arthritis 40% (42 patients). Polyarticular RF negative arthritis 22.9% (24 patients). Enthesitis-Related arthritis 15.2% (16 patients). Polyarticular RF positive arthritis 3.8% (4 patients). Psoriatic arthritis 3.8% (4 patients). Total 100 treatments: 49% adalimumab, 46% etanercept, 5% Tocilizumab. Median time of 36 months overall monitoring (SD ± 21.8). Continue with the drug 45 patients, 45 achieved remission or regimen decrease (23 adalimumab, 20 etanercept, 2 tocilizumab), replaced by inefficiency 7, suspended for toxicity 3. Namely 45 and 55 censored events cases. Medians for survival time: 56 months adalimumab (95% CI 46.5–65.5), 48 months etanercept (95% CI 38.8–57.2), Tocilizumab 46 months. The comparison between the survival curves of etanercept and adalimumab (Logrank) was 0.092 (p=0.762). <h3>Conclusions</h3> The time when "survive" (remain) biological treatment are significantly prolonged, over 4 years, with little difference between the two treatments used (etanercept and adalimumab). In addition, it can be deduced that serious side effects are rare, since in this cohort were replaced only in three cases by significant adverse effects. No significant differences in the comparison of the survival curves of the main biological treatments used were found. <h3>Disclosure of Interest</h3> None declared
Different Patterns of AML1 Mutations between De Novo Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Authors: Lee-Yung Shih, Der-Cherng Liang, Chein-Fuang Huang, Ming-Chung Kuo, Tung-Liang Lin, Jen-Fen Fu, Yu-Shu Shih, Jin-Hou Wu, Po-Nan Wang, Po Dunn, Tzung-Chih Tang, Hung Chang
Journal: Blood (2007)
OP0241 Repetitive Prolonged Physical Workload Is Associated with Increased Risk of Developing Rheumatoid Arthritis: Results from The Swedish Eira-Study
Authors: P. Zeng, L. Klareskog, L. Alfredsson, C. Bengtsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Physical workloads and physical activities/exercises differ in quantity, intensity and duration of mechanical stress exerted on the joint and synovia. There are various types of repetitive prolonged physical workload (RPPW) that have been hypothesized to provide stress to the joints and possibly influence the development of arthritis. To our knowledge, there is no study that investigates the association of various types of RPPW and risk of rheumatoid arthritis (RA). <h3>Objectives</h3> To investigate the association between exposure to 7 different types of RPPW and risk of rheumatoid arthritis; to study the potential interactions between different RPPWs and the genes in the human leukocyte antigen (HLA) region. <h3>Methods</h3> Data from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA), a population-based case-control study involving incident cases of RA (3680 cases and 5935 controls), were analyzed. Information on different types of self-reported RPPW exposures (see figure 1), anti-citrullinated protein antibody (ACPA) status and <i>HLA-DRB1</i> genotypes of cases and controls were retrieved. RPPW exposed subjects were compared with that of unexposed subjects. Odds ratios (ORs) with 95% confidence intervals (CI) of RA (overall), ACPA-positive RA and ACPA-negative RA associated with various RPPW exposures were estimated using an unconditional logistic regression model. Age, sex, residential area, smoking status, alcohol consumption, body mass index and education were considered as potential confounders and added as covariates in the statistical model. RPPW-HLA interactions were evaluated using the principle of departure from additivity of effects, by calculating the attributable proportion (AP) due to interaction. <h3>Results</h3> As shown on figure 1, the estimated ORs of developing RA associated with various RPPW exposures ranged from 1.3 (95% CI, 1.1–1-4) to 1.8 (95%CI, 1.6–2.0). No major difference in the ORs between ACPA-positive and ACPA-negative RA was found. Significant interactions between RPPW exposures and <i>HLA-DRB1</i> shared epitope genes were observed among ACPA-positive RA (AP values ranging from 0.3 (95% CI, 0.1–0.5) to 0.4 (95%CI, 0.2–0.6)). <h3>Conclusions</h3> Repetitive prolonged physical workload (RPPW) is associated with the risk of both ACPA-positive and ACPA-negative RA. The interactions between some RPPWs and <i>HLA-DRB1</i> shared epitope may be involved in the etiology of ACPA-positive RA. <h3>Acknowledgement</h3> The authors thank the investigators and participants from the EIRA study. The authors also thank Marie-Louise Serra and Lena Nise for data collection and Lena Israelsson for performing ELISA analysis. <h3>Disclosure of Interest</h3> None declared
Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.
Authors: Jean-Luc Harousseau, Donna Weber, Meletios Dimopoulos, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, David Siegel
Journal: Blood (2007)
Clinical and Pharmacokinetic Evaluation of Prophylactic Micafungin 150mg Daily Against Invasive Fungal Infections in Cord Blood Transplant Recipients
Authors: Yuki Asano-Mori, Hikari Ota, Aya Nishida, Taichi Ikebe, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Naoyuki Uchida, Koji Izutsu, Akiko Yoneyama, Shigeyoshi Makino, Satoshi Kishino, Shuichi Taniguchi
Journal: Blood (2011)
The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma
Authors: Natasha Kekre, Francisco J Marquez-Malaver, Dolores Caballero, Jl Piñana, Albert Esquirol, Robert J. Soiffer, Monica Cabrero, MJ Terol, Rodrigo Martino, Joseph H. Antin, L Lopez Corral, Carlos Solano, Philippe Armand, Jose A. Perez-Simon
Journal: Blood (2015)
Cyclosporine Versus Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Matched Related and Unrelated Minimal Intensity Allotransplantation.
Authors: Robert P. Nelson, Jennifer E. Schwartz, Menggang Yu, Michael Robertson, Paul R. Haut, Lisa L. Wood, Elizabeth A. Cox, Kenneth Cornetta, Rafat Abonour
Journal: Blood (2007)